Amphetamine-stimulated cortical acetylcholine release: role of the basal forebrain

被引:25
作者
Arnold, HM
Fadel, J
Sarter, M
Bruno, JP
机构
[1] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[2] Venderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37213 USA
[3] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA
关键词
acetylcholine; dopamine; basal forebrain; microdialysis; prefrontal cortex;
D O I
10.1016/S0006-8993(00)03328-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Systemic administration of amphetamine results in increases in the release of acetylcholine in the cortex. Basal forebrain mediation of this effect was examined in three experiments using microdialysis in freely-moving rats. Experiment 1 examined whether dopamine receptor activity within the basal forebrain was necessary for amphetamine-induced increase in cortical acetylcholine by examining whether intra-basalis perfusion of dopamine antagonists attenuates this increase. Systemic administration of 2.0 mg/kg amphetamine increased dopamine efflux within the basal forebrain nearly 700% above basal levels. However, the increase in cortical acetylcholine efflux following amphetamine administration was unaffected by intra-basalis perfusions of high concentrations of D1- (100 muM SCH 23390) or D2-like (100 muM sulpiride) dopamine receptor antagonists. Experiments 2 and 3 determined whether glutamatergic or GABAergic local modulation of the excitability of the basal forebrain cholinergic neurons influences the ability of systemic amphetamine to increase cortical acetylcholine efflux. In Experiment 2, perfusion of kynurenate (1.0 mM), a non-selective glutamate receptor antagonist, into the basal forebrain attenuated the increase in cortical acetylcholine produced by amphetamine. Experiment 3 revealed that positive modulation of GABAergic transmission by bilateral intra-basalis infusion of the benzodiazepine receptor agonist chlordiazepoxide (40 mug/hemisphere) also attenuated the amphetamine-stimulated increase in conical acetylcholine efflux. These data suggest that amphetamine increases cortical acetylcholine release via a complex neuronal network rather than simply increasing basal forebrain D1 or D2 receptor activity. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:74 / 87
页数:14
相关论文
共 58 条
[11]  
Fadel J, 2001, SYNAPSE, V39, P201, DOI 10.1002/1098-2396(20010301)39:3<201::AID-SYN1001>3.0.CO
[12]  
2-3
[13]   ANTAGONISTIC INTERACTION BETWEEN ADENOSINE A(2A) RECEPTORS AND DOPAMINE D-2 RECEPTORS IN THE VENTRAL STRIOPALLIDAL SYSTEM - IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA [J].
FERRE, S ;
OCONNOR, WT ;
SNAPRUD, P ;
UNGERSTEDT, U ;
FUXE, K .
NEUROSCIENCE, 1994, 63 (03) :765-773
[14]  
GAYKEMA RP, 1991, J COMP NEUROL, V202, P563
[15]   Glutamatergic modulation of cortical acetylcholine release in the rat: A combined in vivo microdialysis, retrograde tracing and immunohistochemical study [J].
Giovannini, MG ;
Giovannelli, L ;
Bianchi, L ;
Kalfin, R ;
Pepeu, G .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1997, 9 (08) :1678-1689
[16]   Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site [J].
Gong, W ;
Neill, DB ;
Lynn, M ;
Justice, JB .
NEUROSCIENCE, 1999, 93 (04) :1349-1358
[17]   6-Hydroxydopamine lesion of ventral pallidum blocks acquisition of place preference conditioning to cocaine [J].
Gong, WH ;
Neill, D ;
Justice, JB .
BRAIN RESEARCH, 1997, 754 (1-2) :103-112
[18]   THE IDENTIFICATION OF SOME SOURCES OF AFFERENT INPUT TO THE RAT NUCLEUS BASALIS MAGNOCELLULARIS BY RETROGRADE TRANSPORT OF HORSERADISH-PEROXIDASE [J].
HARING, JH ;
WANG, RY .
BRAIN RESEARCH, 1986, 366 (1-2) :152-158
[19]   Effect of amphetamine on extracellular acetylcholine and monoamine levels in subterritories of the rat medial prefrontal cortex [J].
Hedou, G ;
Homberg, J ;
Martin, S ;
Wirth, K ;
Feldon, J ;
Heidbreder, CA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 390 (1-2) :127-136
[20]   EFFECT OF CENTRAL STIMULANT DRUGS ON ACETYLCHOLINE RELEASE FROM RAT CEREBRAL CORTEX [J].
HEMSWORTH, BA ;
NEAL, MJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1968, 34 (03) :543-+